Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically proven ovarian epithelial cancer
• •* Progressive disease during or after completion of at least one platinum based chemotherapy regimen
• •Bidimensionally measurable disease
• •* At least 2 cm by x-ray, CT scan, or ultrasound
• •No active, symptomatic brain metastases (e.g., cerebral edema and/or progressive tumor growth)
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •WHO 0-2
• •Life expectancy:
• •At least 12 weeks
• •Hematopoietic:
• •Hemoglobin at least 10 g/dL
• •WBC at least 4,000/mm3
• •Platelet count at least 100,000/mm3
• •Hepatic:
• •Bilirubin no greater than 1.7 mg/dL
• •AST/ALT no greater than 2.5 times upper limit of normal (ULN) (no greater than 5 times ULN if liver metastases present)
• •Renal:
• •Creatinine no greater than 1.4 mg/dL
• •Other:
• •No active, uncontrolled infection
• •No nonmalignant systemic disease which would increase risk to patient
• •No other malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 2 months after study
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 4 weeks since prior immunotherapy and recovered
• •Chemotherapy:
• •See Disease Characteristics
• •At least 4 weeks since prior chemotherapy (6 weeks since nitrosoureas or mitomycin) and recovered
• •No more than 2 prior multidrug chemotherapy regimens
• •No more than 1 prior single agent chemotherapy regimen
• •Endocrine therapy:
• •At least 4 weeks since prior endocrine therapy and recovered
• •No concurrent steroids
• •Concurrent hormone replacement therapy allowed
• •Radiotherapy:
• •At least 4 weeks since prior radiotherapy (excluding palliative therapy) and recovered
• •No concurrent radiotherapy
• •Surgery:
• •At least 4 weeks since prior major thoracic or abdominal surgery
• •Other:
• •No other concurrent anticancer therapy or investigational drugs